---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000551"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:23:51.423395+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River Q1 revenue $913.9M (+10.8%), GAAP EPS $1.81, non-GAAP EPS $2.75

## Summary
- Q1 revenue $913.9M (+10.8% YoY); organic growth 9.4%; GAAP net income $93.0M (+51.2%); non-GAAP net income $141.1M (+9.3%).
- Segment revenue: RMS $176.5M (flat), DSA $544.3M (+8.6%), Manufacturing $193.1M (+31.8% driven by CDMO acquisitions).
- 2022 guidance updated: reported revenue growth raised to 13.5%-15.5% (from 13-15%); organic growth unchanged 12.5%-14.5%; non-GAAP EPS reaffirmed $11.50-$11.75.
- DSA segment reported record booking activity and strong backlog growth, with studies booked into 2023.
- Foreign currency reduced reported revenue growth by 1.7%; acquisitions contributed 4.7%.

## SEC filing metadata
- accession: 0001157523-22-000551
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752322000551/0001157523-22-000551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752322000551/a52706413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000551
- JSON: https://secwatch.observer/filing/0001157523-22-000551.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.